Clinical trials: Sexually Transmitted Infection (STI)
Infections, Papillomavirus
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's HPV vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in countries for which the…
- Trial name
- NCT01249365
- Testing
- GSK580299 (Cervarix)
- Where
- 15 sites in Australia, Portugal and 2 more
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
- Trial name
- NCT00157950
- Testing
- Gardasil™
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
CCTG 590 is a open-label study to evaluate the impact of therapy intensification with Maraviroc (MVC) (a CCR5 inhibitor) to a stable suppressive HIV antiretroviral regimen on the rate of CD4+ T-cell recovery and gene expression…
- Trial name
- NCT00925756
- Testing
- Maraviroc
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Diego
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
This study has 2 parts: Phase 1A and Phase 1B. The primary objectives of Phase 1A are to evaluate the safety of KITE-439 and to determine a recommended Phase 1B dose.
- Trial name
- NCT03912831
- Testing
- KITE-439, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- Gilead Sciences
Tuberculosis, HIV Infections
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety…
- Trial name
- NCT01404312
- Testing
- Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
- Where
- 45 sites in United States, Botswana and 8 more
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention
Purpose: To test the feasibility, acceptability of the IA intervention (four telenovela episodes), assessment of the mechanisms of action (self-efficacy, narrative engagement, and emotional elicitation) and conduct a randomized…
- Trial name
- IA (NCT05358366)
- Testing
- Infeccion de Amor (Love Infection)
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Peripheral Neuropathy, HIV Infections
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy
- Trial name
- NCT00264875
- Testing
- pregabalin
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 220 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
HIV/AIDS
INcentives and ReMINDers to Improve Long-term Medication Adherence
The study will test the feasibility and acceptability of using text messages and behavioral economics-based incentives to support anchoring Anti-Retroviral Therapy (ART) adherence to an existing routine in order to improve…
- Trial name
- INMIND (NCT05131165)
- Testing
- Daily Text Messages, Incentivization based on timely ART adherence
- Where
- Uganda
- Volunteers
- 166 people
- Sponsor
- RAND
Syphilis
Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
Syphilis remains a significant health problem worldwide, with an estimated 10.6 million new cases per year. Due to shared transmission route and risk factors, co-infection with syphilis and Human Immunodeficiency Virus (HIV) is…
- Trial name
- NCT02611765
- Testing
- Benzathine penicillin G intramuscular 7.2 million units, Benzathine penicillin G intramuscular 2.4 million units
- Volunteers
- 64 people
- Sponsor
- Baylor College of Medicine
HIV Infections
Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
To evaluate the management of HIV-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of France.
- Trial name
- RACING (NCT01048671)
- Testing
- Raltegravir, ARV (non-raltegravir)
- Volunteers
- 482 people
- Sponsor
- Merck Sharp & Dohme LLC
Sexual Risk Behavior, Drug Use
eHealth Evidence-based Intervention (EBI) for Latino Youth in Primary Care
The purpose of this study is to test the relative effectiveness of a Hispanic-specific eHealth intervention, "e-Health Familias Unidas," in preventing and reducing drug use, sexual risk behaviors, and STIs among Hispanic youth in…
- Conditions
- Sexual Risk Behavior, Drug Use, Family Functioning
- Trial name
- NCT03009539
- Testing
- eHealth Familias Unidas Primary Care
- Where
- 12 sites in United States
- Volunteers
- 921 people, healthy volunteers welcome
- Sponsor
- University of Miami
HIV Infections
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
This single arm study will evaluate the efficacy, safety and tolerability of a new investigational protease inhibitor (PI) plus background antiretrovirals plus Fuzeon (90mg sc bid) in HIV-1 infected, triple-class…
- Trial name
- NCT00326963
- Testing
- Background ARVs, PI, enfuvirtide [Fuzeon]
- Where
- 38 sites in United States, Australia
- Volunteers
- 142 people
- Sponsor
- Hoffmann-La Roche
External Genital Warts
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%.
- Trial name
- NCT02482428
- Testing
- Investigational Treatment, Aldara
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
HIV/AIDS, Health Behaviors
Expanding HIV Testing Among Uganda Adults Who Utilize Traditional Healers
HIV antiretroviral therapy has the potential to dramatically decrease HIV transmission worldwide1; yet, a barrier to ending the AIDS epidemic in low-resource settings is the fact that healthcare is largely provided by traditional…
- Trial name
- NCT03718871
- Testing
- HIV testing at traditional healer practices
- Where
- Uganda
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
HIV Infection
Dipyridamole for Immune Activation in HIV
The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral load.
- Trial name
- NCT02121756
- Testing
- Dipyridamole
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sharon Riddler
Human Immunodeficiency Virus, Treatment
First in Human Study of TLC-ART 101 (ACTU 2001)
This study is a prospective, open-label, single-site, first-in-human study of a long-acting, injectable combination antiretroviral therapy platform, with a pharmacologically-guided adaptive design for dose escalation…
- Conditions
- Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
- Trial name
- NCT05850728
- Testing
- TLC-ART
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg…
- Trial name
- NCT00146328
- Testing
- Tipranavir
- Where
- 233 sites in United States, Argentina and 16 more
- Volunteers
- 997 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more…
- Trial name
- NCT00447902
- Testing
- tipranavir, ritonavir
- Where
- 30 sites in United States, Argentina and 5 more
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
HIV Infection
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study
The purpose of this study is to learn whether having the AMP Study antibody (called VRC01) in a person's body might help their immune system control HIV better, even without HIV medication called antiretroviral therapy or ART, if…
- Trial name
- NCT04860323
- Testing
- Analytical Treatment Interruption
- Where
- 11 sites in Botswana, Malawi and 2 more
- Volunteers
- 13 people
- Sponsor
- HIV Vaccine Trials Network
Gonorrhea, Chlamydia
Adolescent Sexually Transmitted Infection Screening in the Emergency Department
Sexually transmitted infections (STIs) are highly prevalent among adolescents. Clinical practices related to screening, diagnosis, treatment, and prevention of STIs among adolescents are suboptimal.
- Trial name
- STI (NCT03715335)
- Testing
- Targeted STI Screening, Universally Offered STI Screening
- Where
- 5 sites in United States
- Volunteers
- 98,413 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.